Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Jefferson Research
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Alexion Pharmaceuticals Inc Reaffirms FY 2012 Guidance-Conference Call
Alexion Pharmaceuticals Inc raised fiscal 2012, it expects revenue of $1.120 to $1.130 billion and non-GAAP earnings per share (EPS) to be in the range of $1.99 to $2.04 per share. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenues of $1.129 and EPS of $2.02 for fiscal 2012.
Latest Developments for Alexion Pharmaceuticals Inc
- Alexion Pharmaceuticals Inc Raises FY 2013 Guidance
- Alexion Pharmaceuticals Inc Reaffirms FY 2013 Guidance-Conference Call
- Alexion Pharmaceuticals Inc Issues FY 2013 Guidance Above Analysts' Estimates
- Alexion Pharmaceuticals Inc Raises FY 2012 Revenue Guidance; Reaffirms FY 2012 EPS Guidance-Conference Call
Latest Key Developments in Pharmaceuticals
- AmerisourceBergen Corp Reaffirms FY 2013 EPS Gudiance-Conference Call
- Immunotec Inc Announces New CEO
- Novo Nordisk A/S Reports Positive Results from First Phase 3 Trial with Long-Acting Factor IX for Treatment of Haemophilia B
- Sanofi SA Announces Positive Results on Pivotal Study of Inhibitor in Myelofibrosis-DJ
- Share this
- Link this
- Digg this
Follow Reuters